News
Daunorubicine was purchased from Pfizer (Berlin, Germany), BEZ-235, AC220, AZD-6244 and MK-2206 from Selleck Chemicals (Houston, TX, USA), rapamycin from LC Laboratories (Woburn, MA, USA) and ...
The FDA previously granted breakthrough therapy designation to ziftomenib for relapsed/refractory NPM1-mutant AML.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback